"It would be significant if the Phase III results match the interim lenzilumab results, said Badley, adding it would see wide uptake if approved." https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/